BioSpace News Archive

Virpax ® Pharmaceuticals, Inc. today announced that it expects to submit an Investigational New Drug Administration on the Company’s Pre-IND submission. If successful, that would allow clinical trials to begin by the middle of 2024.

BerGenBio ASA today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib will be presented at the Society for Immunotherapy for Cancer (SITC) meeting being held on November 1-5, 2023 in San Diego, California.

Endovascular Engineering (“E2"), a mission driven, venture-backed, medical device company focused on the development and deployment of next generation clot removal technologies, announced today positive initial results from its ENGULF study.

Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company’s new Executive Vice President, Chief Legal & Compliance Officer.

YourBio Health, a Boston-based pioneer in remote, capillary whole blood collection technology, today announced that it has received further regulatory approval for its TAP® Micro Select blood collection device with certification for CE Marking.

Florida Cancer Specialists & Research Institute, LLC is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma.

Theratechnologies Inc. announced that it has closed its previously announced public offering of 12,500,000 common shares of the Company at a public offering price of US$1.00 per Common Share.

Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. (“Lung Tx”).